University of Kentucky

Alpacas Could be the Secret Weapon Against COVID-19

18-Jun-2020 8:25 AM EDT, by University of Kentucky

Newswise — LEXINGTON, Ky. (June 18, 2020)  Alpacas Big Boy, Blue Eyes and Emperor may hold the key to combating COVID-19. Their antibodies could offer a defense against SARS-CoV-2, the virus that causes the disease.

University of Kentucky College of Medicine researchers are using the special antibodies made by alpacas, called nanobodies, to help understand the novel coronavirus and potentially develop a treatment that could protect people from being infected. 

Nanobodies are smaller and more stable types of antibodies taken from the immune systems of camelids – which include camels, llamas and alpacas. Nanobodies could be more effective at fighting the disease because their tiny size gives them the ability to fit into spaces on viral proteins that regular antibodies have a hard time penetrating.

“The idea is that nanobodies are small enough to access small pockets on SARS-CoV-2’s spike proteins, which is the part of the virus that attaches to host cells. A nanobody that could block the binding of the spike protein to its cellular receptor could be an effective treatment for COVID-19,” said Sidney Whiteheart, who is co-leading the study with Lou Hersh, both professors in the Department of Molecular & Cellular Biochemistry.

With the help of Big Boy, Blue Eyes and Emperor, Hersh and Whiteheart’s research team is generating nanobodies that can bind to the spike protein and therefore, neutralize the virus.

The alpaca trio have been immunized with isolated proteins from SARS-CoV-2 and then researchers collect samples of their blood containing nanobodies produced by their immune systems. In the lab, the nanobodies are extracted, tested, and reproduced at a larger scale for use in research and for therapeutic development.

Virus-binding nanobodies from the alpacas can confer passive immunity in humans and thus help fight a SARS-CoV-2 infection. While passive immunity from a disease is shorter-lived compared to the protection one’s own immune response would provide, it helps protect right away—something that could be valuable as we wait for a vaccine, Hersh says.

“Nanobodies have many qualities that make them ideal for therapeutic development, particularly for COVID-19,” said Hersh. “They are small and stable, making them easier to manipulate, and they can be produced more rapidly and in large quantities at a low cost. They are also easily tolerated by the human immune system and could potentially be inhaled for rapid delivery to the lungs.”

Given their special properties, nanobodies are not new to the fight against disease, with researchers—including those at UK—investigating their potential against HIV and other viruses for many years.

The UK team, including Martin Chow and Craig Vander Kooi along with Hersh and Whiteheart, have shown that the alpacas are producing antibodies against the SARS-CoV-2 spike protein, and anticipate having nanobodies in the next few weeks. They will then begin testing these nanobodies as therapeutic agents by testing for their ability to prevent SARS-CoV-2 from interacting with its target cells.

Big Boy, Blue Eyes and Emperor have contributed to UK’s nanobody research for more than three years.

While the three come to UK’s North Farm twice a year to get vaccinated and have blood drawn, they live at River Hill Ranch, an alpaca farm near Richmond. The partnership with UK is a win-win situation, says farm owner Alvina Maynard.

The trio are favorites among those visiting Maynard’s farm for alpaca-themed field trips, camps and yoga lessons. And as part of her herd, their fleece is also used to make artisan socks, scarves and sweaters.

“They are supporting local business and we are supporting groundbreaking and potentially lifesaving research,” says Maynard. “I’m beyond thrilled that our alpacas can serve this greater purpose.”

In the past three years, the alpacas have helped UK researchers generate more than 50 nanobodies to target proteins involved in a variety of human diseases including cancer, diabetes and neurological disorders.

The current COVID-19 nanobody research is funded in part by a pilot grant from UK’s COVID-19 Unified Research Experts (CURE) Alliance and the Center for Clinical and Translational Science (CCTS). The goal is that data from the project will support more grant funding for additional research.

UK researchers also plan to share the purified nanobodies with colleagues pursuing related COVID-19 research. Those nanobodies that bind to the spike protein could also help scientists understand more about the virus itself and how it is structured. This could aid in the development of other novel types of treatments.

Filters close

Showing results

110 of 2873
access_time Embargo lifts in 2 days
Embargo will expire: 12-Aug-2020 6:00 PM EDT Released to reporters: 11-Aug-2020 11:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 12-Aug-2020 6:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 11-Aug-2020 6:50 PM EDT
Untapped potential for TikTok to convey COVID-19 guidance
De Gruyter

Research published in DeGruyter's International Journal of Adolescent Medicine and Health suggests TikTok is rich with untapped educational potential.

Released: 11-Aug-2020 5:40 PM EDT
Experimental COVID-19 vaccine prevents severe disease in mice
Washington University in St. Louis

Researchers at Washington University School of Medicine in St. Louis have created a COVID-19 vaccine candidate from a replicating virus. This experimental vaccine has proven effective at preventing pneumonia in mice.

Released: 11-Aug-2020 4:15 PM EDT
Medical Organizations Team Up to Help Parents and Caregivers Navigate Return to Sports and Recreation during COVID-19 Pandemic
American Medical Society for Sports Medicine (AMSSM)

The American Academy of Pediatrics (AAP), American Medical Society For Sports Medicine (AMSSM) and National Athletic Trainers’ Association (NATA) have joined forces to address growing concerns and confusion amid youth sports and recreation participation during the coronavirus pandemic.

Released: 11-Aug-2020 4:10 PM EDT
DHS to Hold Virtual Industry Day Seeking Innovative Solutions for Coronavirus Response
Homeland Security's Science And Technology Directorate

DHS S&T is seeking groundbreaking solutions to address current and future operational needs. S&T issued the Emerging Needs: Covid-19 Response & Future Mitigation topic call through its Silicon Valley Innovation Program (SVIP).

Newswise:Video Embedded bouncing-sticking-exploding-viruses-understanding-the-surface-chemistry-of-sars-cov-2
Released: 11-Aug-2020 3:45 PM EDT
Bouncing, Sticking, Exploding Viruses: Understanding the Surface Chemistry of SARS-CoV-2
Michigan Technological University

Better understanding of the surface chemistry of the SARS-CoV-2 virus is needed to reduce transmission and accelerate vaccine design.

Released: 11-Aug-2020 3:05 PM EDT
High Blood Sugar May Worsen COVID-19 Outcomes
Michigan Medicine - University of Michigan

Preliminary observations of COVID-19 patients with diabetes inspired an algorithm for glucose monitoring that’s suspected to help combat the virus’ serious complications.

Showing results

110 of 2873